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Antiviral cytotoxic T lymphocytes (CTL) are specifically induced against viral
antigens presented by MHC class I molecules on the surface of infected cells (1) .
The intracellularly synthesized antigens are processed and associated with class I
antigens within cells in ayet poorly defined way before presentation on the cell sur-
face (2) . Induced effector CTL also recognize synthetic peptides bound by MHC
class I molecules from without on the cell surface in absence of an apparent need
for cell internal processing (3, 4) .
Virus-specific CTL have been shown to be crucially involved in recovery from
and in protection against lymphocytic choriomeningitis virus (LCMV) (5)andmany
othervirus infections . Induction ofCTLresponse is best achieved in vivo by priming
with replicating virus . Since vaccination with live virus may cause, although rarely,
some disease, means have been sought for many years to induce virus-specific CTL
responses in vivo with nonreplicating synthetic virus antigens .
In the past fewyears in vivo primingof class I-restricted T cells with free proteins
or peptides was shown forovalbumin with whole soluble protein (6) or tryptic digests
of thewhole protein or relatively large peptides of the relevantT cell epitope ofoval-
bumin (7, 8) . Recently it was shown that short synthetic peptides of influenza virus
nucleoprotein can induce specific responses in vivo to the priming peptide as well
as to the virus; induction was possible with chemically modified peptides linked to
a lipid component but not with free peptides (9) .
We evaluated whether the free unmodified 15-mer peptide (RPQASGVYMGN-
LTAQ) representing a H-2a T cell epitope ofLCMV nucleoprotein (10, 11) could
induce in vivo a specific CTL response toLCMV and we report on the successful
demonstration ofsuch a response. Although stringently restricted to the class I MHC
allele forthepeptide used, these resultsdemonstrate the feasibility ofusing unmodified
T cell epitope peptides as antiviral vaccines in principal .
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Mice.
￿
Inbred BALB/c mice (H-2d) were purchased from the Institut fur Zuchthygiene,
University of Zurich, Switzerland .
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Virus.
￿
The LCMVWE strain was originallyobtained from Dr. F. Lehmann-Grube, Ham-
burg, FRG, and was grown in L929 fibroblast cells (12). The vaccinia virus WR strain was
grown in BSC-1 cells. Recombinant vaccinia virus expressing amino acids (aa) 1-202 of the
LCMV nucleoprotein (vaccNP2) was constructed and grown as described (10).
Synthetic Peptides.
￿
Peptides were synthesized manually by the solid-phase method (13, 14)
on p-alkoxybenzyl alcohol resin (15). Fluorenylmethyloxycarbonyl (Fmoc-) strategy was used
throughout the synthesis (Fmoc-N-a and TU side chain protection) (14). Peptides were
cleaved from the resinby 55 % trifluoroacetate in dichloromethane, purified by reverse-phase
HPLC, ion-exchanged, and lyophilized. The freeze-dried material was analyzed on an Amino-
quant HP 1046A amino acid analyzer and by (+)FAB mass spectroscopy.
Monoclonal Antibodies.
￿
The mAbs YTS 169.4 (anti-CD8) and YTS 191 .1 (anti-CD4)(16)
and low tox rabbit complement (Cedarlane Laboratories, Ontario, Canada) were used to
deplete lymphocyte subpopulations in vitro.
Priming ofMice and Lymphocyte Cultures.
￿
BALB/c (H-2d) mice were primed subcutaneously
at the base of the tail with 100 1~g free peptide in IFA three times with 1-wk intervals. 7 d
after the last injection lymphocytes from draining lymphnodes were restimulated in vitro
(3 x 106/well) with irradiated syngeneic spleen cells (6 x 106/well) in 24-well Costar plates
in 10% FCS/Iscove's modified Dulbecco Medium for 6 d. Stimulator cells were sensitized
in vitro with 100-200,ugpeptide/ml for 3 h and washed before use. Alternatively, mice were
injected once intravenously with 4 x 106 PFU recombinant vaccinia virus (vaccNP2) and
6 wk later lymphocytes from spleens were restimulated in vitro as described.
Cytotoxiciy Assay.
￿
In vitro restimulated lymphocytes from lymphnodes or spleens or pri-
mary LCMV immune bulk splenocytes from mice infected intravenously with 200 PFU
LCMVWE 8 d previously were tested on appropriate target cells, B10.D2 (H-2d) and DBA/l
(H-29), as described in detail elsewhere (10).
Results and Discussion
Major T Cell Epitope in H-2d Mice.
￿
The major T cell response in BALB/c (H-2d)
mice is directed against the as 112-132 region of LCMV nucleoprotein; the peptide
as 118-132 is well recognized by CTL in association with Ld (10, 11) (Fig. 1 A). The
cytotoxic T cell response of H-2d mice to LCMV resulted in lysis of target cells in-
fected with LCMV or preincubated with peptide as 118-132, but not of target cells
if preincubated with LCMV nucleoprotein peptide as 157-171 (Fig. 1 B). These
two peptides were used in the following studies as relevant/positive (aa 118-132) and
irrelevant/negative (aa 157-171) peptide antigens.
Induction In Vivo of LCMVand Peptide-specific CTL by a T Cell Epitope Peptide.
￿
The
capacity of these peptides to induce a peptide- and virus-specific CTL response in
vivo was evaluated in H-2d mice by subcutaneous injection of unmodified free pep-
tides emulsifiedin IFA. 7 d after the last injection the lymphocytes from the draining
lymphnodes were isolated and restimulated in vitro with irradiated syngeneic spleen
cells coated with the relevant or irrelevant peptide. Lymphocytes from mice primed
with peptide as 118-132 and restimulated with this peptide in vitro generated a specific
cytotoxic T cell response against LCMVinfected and peptide-coated target cells (Fig.
2 A). The response was specific since neither peptide as 157-171-coated target cells
nor vaccinia virus WR-infected target cells were recognized by peptide as 118-
132-primed lymphocytes.
Restimulation of this same effector population was specific since peptide as 157-
171-coated stimulator cells failed to induce a significant response (Fig. 2 B).
When the peptide as 157-171 was used for in vivo priming and peptide as 118-132
for restimulation in vitro, no specific T cell response was generated neither againstl4
￿
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FIGURE 1.
￿
LCMV Tcell epitope in H-2d mice. (A)
Amino acid sequence of the Tcell epitope (peptide
as 118-132) andpeptide as 157-171, whichwasused
as a control peptide in all the studies. (B) Specific
lysisby LCMV immune splenocytes of BIO.D2 (H-
2d) fibroblast cells infected with LCMVWE (/)or
sensitized before the assay with peptide as 118-132
(A) or with peptide as 157-171 (0).
the irrelevant peptide nor the peptide as 118-132 (Fig. 2 C). This result shows that
the relevant peptide as 118-132 cannot readily induce a virus-specific effectorpopu-
lation in vitro. Both primingand restimulation with theirrelevant peptideas 157-171
failed to induce aspecific CTLresponseto anyofthedescribed target cells(Fig. 2D).
Acomparable CTL response is triggered in mice byinfection with arecombinant
vaccinia virus expressing the relevant subregion as 1-202 of the nucleoprotein of
LCMV (10). This subunit vaccine expresses all the nucleoprotein sequences neces-
sary forendogenous processing ofthe antigen (17). Tlymphocytesfrom mice primed
with vaccNP2 (aa 1-202) express specific cytotoxic activity only when restimulated
in vitro with therelevant peptideas 118-132 (Fig. 2E) but not with peptide as 157-171
(Fig. 2 F). The specific effector T cell population induced by peptide as 118-132
in IFA and those induced by recombinant vaccinia virus vaccNP2 and restimulated
in vitro were comparably specific for LCMVinfected target cells and fortarget cells
coated with peptide as 118-132 (Fig. 2 A, E).
In Vivo PeptidePrimed CytotoxicActivity IsMediated by CD8+ andMHCClass I-restricted
T Cells. The following experiments were performed to exclude that free peptides
might induce CD4+ effector lymphocytes and to confirm that effector cells were clas-
sical CD8i CTLs. Effector T cells induced by peptide as 118-132 in vivo (Fig. 2
A) were susceptible to treatment with anti-CD8 plus complement, whereas treat-
ment with anti-CD4 had no effect (Fig. 3 A).
In vivo peptide-primed cytotoxic T cells ofBALE/c (H-2d) origin were tested on
syngeneic (H-2d, B10.D2) and allogeneic (H-2v, DBA/1) target cells infected with
LCMV Both target cells do not express class II MHC antigens. There is a clear
restriction specificity for H-2d target cells (Fig. 3 B); this specificity control is par-
ticularly convincing since the same T cell epitope defined by peptide as 118-132 of
LCMV nucleoprotein is recognized on H-2 Ld (10, 18) and H-2 L9 (Schulz, M.,
P Aichele, R. M. Zinkernagel, and H. Hengartner, manuscript in preparation).1818
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FIGURE 2.
￿
Peptide- and virus-specific CTL priming in vivo. BALB/c (H-2d) mice were primed
either by 3x injection s.c. with peptide as 118-132 (A, B) or peptide as 157-171 (C, D), or once
by i.v. injectionofrecombinant vaccinia virusvaccNP2 (aa 1-202) (E,F) . Draining lymphnode
cells(A-D)or spleen cells(E, F) were prepared and restimulated in vitro with irradiated spleen
cells, which were incubated before either with peptide as 118-132 (A, C, E) or with peptide as
157-171 (B, D, F). After 6 d in culture, cytotoxic activity was tested on syngeneic target cells
infected with LCMVWE (/) or vaccinia virus WR (O), or target cells sensitized before with
peptide as 118-132 (A) or peptide as 157-171 (0).
The present results show that unmodified viral peptides mixed with a mild adju-
vant (notcontaining BCG)are able to induce MHC-dependent, virus-specific cyto-
toxic Tcells in vivo. Together with the recent demonstration that peptides covalently
linked to a lipid component (9) can readily induce aCTL response, thepresent evi-
dence suggeststhatcocktails ofviral peptides maybeused as antiviral Tcellvaccines.
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FIGURE 3. Peptide-primed effector cells are
CD8' and MHC class I restricted. CTL of
BALB/c (H-2d) were primed in vivo and restim-
ulated in vitro with the relevant peptide as
118-132. (A) Effector populations were depleted
ofCD4' (0)or CD8* (O)cells by specific anti-
body plus complement treatmentandremaining
specific lysis was tested on LCMVWE infected
target cells. (B) Lysis of B10.D2 (H-2d) (O) or
DBA/l (H-2q) (/) fibroblasts infected with
LCMVWE by in vivo peptide-primed CTL;
these fibroblast cell lines are MHC class II an-
tigens-negative.Summary
Induction in vivo of antiviral cytotoxic T cell response was achieved in a MHC
class I-dependent fashion by immunizing mice three times with a free unmodified
15-mer peptide derived from the nucleoprotein oflymphocytic choriomeningitis virus
in IFA. The effector T cells are CD8+ , restricted to the class I Ld allele of the ana-
lyzed mouse strain, and are specific both at the level of secondary restimulation in
vitro and at the effector T cell level. These results suggest that cocktails ofviral pep-
tides may be used as antiviral T cell vaccines.
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